Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers

EBioMedicine

Volumn 2, Issue 10, 2015, Pages 1331-1339

  Widschwendter, Martin ^a   Burnell, Matthew ^a   Fraser, Lindsay ^a   Rosenthal, Adam N ^a   Philpott, Sue ^a   Reisel, Daniel ^a   Dubeau, Louis ^b   Cline, Mark ^c   Pan, Yang ^d   Yi, Ping Cheng ^d   Gareth Evans, D ^e   Jacobs, Ian J ^a,f   Menon, Usha ^a   Wood, Charles E ^c   Dougall, William C ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d AMGEN INC   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

BRCA1 and BRCA2 mutations; Breast cancer; Cancer prevention; Carcinogenesis; OPG; RANKL

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST; BREAST CANCER; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; MACACA FASCICULARIS; MALE; MAMMARY GLAND; MENSTRUAL CYCLE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BLOOD; CASE CONTROL STUDY; CELL TRANSFORMATION; CLINICAL TRIAL; GENE EXPRESSION REGULATION; GENETICS; GERMLINE MUTATION; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HETEROZYGOTE; METABOLISM; MULTICENTER STUDY; MUTATION; OUTCOME ASSESSMENT; POSTMENOPAUSE; RISK FACTOR; TUMOR SUPPRESSOR GENE;

ANIMALS; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HETEROZYGOTE; HORMONES; HUMANS; MACACA FASCICULARIS; MUTATION; OSTEOPROTEGERIN; PATIENT OUTCOME ASSESSMENT; POSTMENOPAUSE; RANK LIGAND; RISK FACTORS;

EID: 84951909171     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.08.037     Document Type: Article

References (43)

1. Benagiano G., Bastianelli C., Farris M., Brosens I. Selective progesterone receptor modulators: an update. Expert. Opin. Pharmacother. 2014, 15:1403-1415.
2. Beral V. Breast cancer and hormone-replacement therapy in the million women study. Lancet 2003, 362:419-427.
3. Brisken C. Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat. Rev. Cancer 2013, 13:385-396.
4. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women's health initiative randomized trial. JAMA 2003, 289:3243-3253.
5. Chodankar R., Kwang S., Sangiorgi F., et al. Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Curr. Biol. 2005, 15:561-565.
6. Cline J.M., Register T.C., Clarkson T.B. Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys. Menopause 2002, 9:422-429.
7. Cuzick J., Sestak I., Forbes J.F., et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014, 383:1041-1048.
8. Cuzick J., Sestak I., Cawthorn S., et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015, 16:67-75.
9. Domchek S.M., Friebel T.M., Singer C.F., et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010, 304:967-975.
10. Dubeau L. Pathogenesis of serous, extra-uterine müllerian epithelial cancer and therapeutic implications. Transl. Cancer Res. 2015, 4:3-13.
11. Eghbali-Fatourechi G., Khosla S., Sanyal A., et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 2003, 111:1221-1230.
12. Fackenthal J.D., Olopade O.I. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat. Rev. Cancer 2007, 7:937-948.
13. Findlay D., Chehade M., Tsangari H., et al. Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Res. Ther. 2008, 10:R2.
14. Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008, 9:45-53.
15. Foulkes W.D., Metcalfe K., Sun P., et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin. Cancer Res. 2004, 10:2029-2034.
16. Fourkala E.O., Zaikin A., Burnell M., et al. Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. Endocr. Relat. Cancer 2012, 19:137-147.
17. Gnant M., Pfeiler G., Dubsky P.C., et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015.
18. Gonzalez-Suarez E., Jacob A.P., Jones J., et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468:103-107.
19. Haynes B.P., Viale G., Galimberti V., et al. Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer. Breast Cancer Res. Treat. 2014, 148:327-335.
20. Hong H., Yen H.Y., Brockmeyer A., et al. Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer. Cancer Res. 2010, 70:221-228.
21. Hu H., Wang J., Gupta A., et al. RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase. Breast Cancer Res. Treat. 2014, 146:515-523.
22. Joshi P.A., Jackson H.W., Beristain A.G., et al. Progesterone induces adult mammary stem cell expansion. Nature 2010, 465:803-807.
23. Kaaks R., Tikk K., Sookthai D., et al. Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status - results from the EPIC cohort. Int. J. Cancer 2014, 134:1947-1957.
24. Key T.J., Appleby P.N., Reeves G.K., et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br. J. Cancer 2011, 105:709-722.
25. Key T.J., Appleby P.N., Reeves G.K., et al. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol. 2013, 14:1009-1019.
26. Kim J., Oktay K. Baseline E(2) levels are higher in BRCA2 mutation carriers: a potential target for prevention?. Cancer Causes Control 2013, 24:421-426.
27. Lambert P.C., Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009, 9:265-290.
28. Metcalfe K., Lynch H.T., Foulkes W.D., et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol. 2015, 1:306-313.
29. Poole A.J., Li Y., Kim Y., Lin S.C., Lee W.H., Lee E.Y. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006, 314:1467-1470.
30. Rebbeck T.R., Mitra N., Wan F., et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 2015, 313:1347-1361.
31. Robson M., Offit K. Clinical practice. management of an inherited predisposition to breast cancer. N. Engl. J. Med. 2007, 357:154-162.
32. Sanger N., Ruckhaberle E., Bianchini G., et al. OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer. Mol. Oncol. 2014, 8:1196-1207.
33. Santini D., Schiavon G., Vincenzi B., et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One 2011, 6.
34. Schramek D., Leibbrandt A., Sigl V., et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468:98-102.
35. Schramek D., Sigl V., Penninger J.M. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol. Metab. 2011, 22:188-194.
36. Segev Y., Rosen B., Lubinski J., et al. Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. Fam Cancer 2015, (April 3 [Epub ahead of print]).
37. Titus S., Li F., Stobezki R., et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci. Transl. Med. 2013, 5. (172ra21).
38. Venkitaraman A.R. Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science 2014, 343:1470-1475.
39. Veronesi U., Boyle P., Goldhirsch A., Orecchia R., Viale G. Breast cancer. Lancet 2005, 365:1727-1741.
40. Vik A., Brodin E.E., Mathiesen E.B., et al. Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromso study. Eur. J. Epidemiol. 2015, 30:219-230.
41. Widschwendter M., Rosenthal A.N., Philpott S., et al. The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. Lancet Oncol. 2013, 14:1226-1232.
42. Wood C.E., Branstetter D., Jacob A.P., et al. Progestin effects on cell proliferation pathways in the postmenopausal mammary gland. Breast Cancer Res. 2013, 15:R62.
43. Yen H.Y., Gabet Y., Liu Y., et al. Alterations in Brca1 expression in mouse ovarian granulosa cells have short-term and long-term consequences on estrogen-responsive organs. Lab. Investig. 2012, 92:802-811.